Introduction: Despite many therapeutic options available only one-third of hypertensive patients achieve target Blood pressure (BP). Different clinical studies have reported that reducing the blood pressure can substantially decrease cardiovascular risk and all cause mortality. Aim: The present study was undertaken to evaluate the efficacy and safety of, fixed dose combination of Olmesartan 40 mg + Chlorthalidone 12.5mg, in the management of hypertension uncontrolled with Olmesartan monotherapy. Materials and Method: 105 patients were enrolled in this postmarketing surveillance (PMS) study. Patients were prescribed to take fixed dose combination for 60 days. Result: There was a significant decrease (p<0.0001) in systolic blood pressure (SBP) & diastolic blood pressure (DBP) from the baseline to 15th, 30th and 60th days of the treatment. At the end of the study period of 60 days 93.4% & 91.6 % patients of age group >60 years and <60 years achieved the Joint National Committee (JNC VIII) recommended goal respectively. (<150/90 for elder patients aged above 60 year and 140/90 for those aged less than 60 years). Conclusion: Thus fixed dose combination therapy of Olmesartan & Chlorthalidone has been shown to be excellent in efficacy and tolerability & gives another option for the optimal management of hypertension.
